{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:16:04Z","timestamp":1790705764750,"version":"4.1.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12933-019-0864-7","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T13:02:47Z","timestamp":1559653367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1) paradigm: conceptual framework and therapeutic potential"],"prefix":"10.1186","volume":"18","author":[{"given":"Jean-Charles","family":"Fruchart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aguilar-Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al Rasadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Amarenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Barter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ceska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Despr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Duriez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Eckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat V.","family":"Ezhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel P.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Karpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Krempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Lorenzatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus Millan","family":"Nu\u00f1ez-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"Packard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos I.","family":"Ponte-Negretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Ruscica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaukat","family":"Sadikot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Shimano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyamitr","family":"Sritara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane K.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Chen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey V.","family":"Susekov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Tartar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Riitta","family":"Taskinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tenenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale S.","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tybj\u00e6rg-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Valensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Vrabl\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Wahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"864_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCRESAHA.117.308903","volume":"121","author":"P Joseph","year":"2017","unstructured":"Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the global burden of cardiovascular disease. Part 1: the epidemiology and risk factors. Circ Res. 2017;121:677\u201394.","journal-title":"Circ Res."},{"key":"864_CR2","unstructured":"World Health Organization. Fact sheet. Obesity and overweight. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight . Accessed 21 Jan 2019."},{"key":"864_CR3","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S0140-6736(18)31992-5","volume":"392","author":"NCD Countdown 2030 collaborators","year":"2018","unstructured":"NCD Countdown 2030 collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet. 2018;392:1072\u201388.","journal-title":"Lancet"},{"key":"864_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"864_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/MEG.0000000000001183","volume":"30","author":"OO Olubamwo","year":"2018","unstructured":"Olubamwo OO, Virtanen JK, Voutilainen A, Kauhanen J, Pihlajam\u00e4ki J, Tuomainen TP. Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction. Eur J Gastroenterol Hepatol. 2018;30:1047\u201354.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"864_CR6","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315\u201381.","journal-title":"Eur Heart J"},{"key":"864_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1517\/14740338.5.1.145","volume":"5","author":"MH Davidson","year":"2006","unstructured":"Davidson MH. Statin\/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006;5:145\u201356.","journal-title":"Expert Opin Drug Saf."},{"key":"864_CR8","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.2337\/dc11-1811","volume":"35","author":"JC Mychaleckyj","year":"2012","unstructured":"Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care. 2012;35:1008\u201314.","journal-title":"Diabetes Care"},{"key":"864_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","volume":"54","author":"TM Davis","year":"2011","unstructured":"Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011;54:280\u201390.","journal-title":"Diabetologia"},{"key":"864_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/17425255.2018.1483337","volume":"14","author":"MS Hedrington","year":"2018","unstructured":"Hedrington MS, Davis SN. Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver. Expert Opin Drug Metab Toxicol. 2018;14:671\u20137.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"Suppl 10","key":"864_CR11","doi-asserted-by":"publisher","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","volume":"102","author":"JC Fruchart","year":"2008","unstructured":"Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(Suppl 10):1K\u201334K.","journal-title":"Am J Cardiol"},{"key":"864_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real-world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163\u201370.","journal-title":"Eur Heart J"},{"key":"864_CR13","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1161\/CIRCULATIONAHA.113.002529","volume":"129","author":"FM Sacks","year":"2014","unstructured":"Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case\u2013control study in 13 countries. Circulation. 2014;129:999\u20131008.","journal-title":"Circulation"},{"key":"864_CR14","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459\u2013572.","journal-title":"Eur Heart J."},{"key":"864_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"864_CR16","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107.","journal-title":"N Engl J Med"},{"key":"864_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137:338\u201350.","journal-title":"Circulation"},{"key":"864_CR18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941\u201350.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"864_CR19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331.","journal-title":"N Engl J Med"},{"key":"864_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2018","unstructured":"Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:219\u201329.","journal-title":"Lancet"},{"key":"864_CR21","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1161\/CIRCULATIONAHA.118.035289","volume":"137","author":"KV Patel","year":"2018","unstructured":"Patel KV, Pandey A, de Lemos JA. Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine. Circulation. 2018;137:2551\u20133.","journal-title":"Circulation"},{"key":"864_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pcad.2018.06.004","volume":"61","author":"ME Pich\u00e9","year":"2018","unstructured":"Pich\u00e9 ME, Poirier P, Lemieux I, Despr\u00e9s JP. Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update. Prog Cardiovasc Dis. 2018;61:103\u201313.","journal-title":"Prog Cardiovasc Dis"},{"key":"864_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","volume":"39","author":"BK Lauridsen","year":"2018","unstructured":"Lauridsen BK, Stender S, Kristensen TS, Kofoed KF, K\u00f8ber L, Nordestgaard BG, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J. 2018;39:385\u201393.","journal-title":"Eur Heart J"},{"key":"864_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2019.01.029","volume":"282","author":"RD Santos","year":"2019","unstructured":"Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis. 2019;282:110\u201320.","journal-title":"Atherosclerosis."},{"key":"864_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11883-016-0614-1","volume":"18","author":"M-R Taskinen","year":"2016","unstructured":"Taskinen M-R, Boren J. Why is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease? Curr Atheroscler Rep. 2016;18:59.","journal-title":"Curr Atheroscler Rep."},{"key":"864_CR26","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","volume":"32","author":"MJ Chapman","year":"2011","unstructured":"Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Bor\u00e9n J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345\u201361.","journal-title":"Eur Heart J"},{"key":"864_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ijcard.2017.05.059","volume":"243","author":"CI Ponte-Negretti","year":"2017","unstructured":"Ponte-Negretti CI, Isea-Perez JE, Lorenzatti AJ, Lopez-Jaramillo P, Wyss-Q FS, Pint\u00f3 X, et al. Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment: expert\u2019s position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS). Int J Cardiol. 2017;243:516\u201322.","journal-title":"Int J Cardiol"},{"key":"864_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2018.11.008","author":"W Fan","year":"2018","unstructured":"Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. J Clin Lipidol. 2018. https:\/\/doi.org\/10.1016\/j.jacl.2018.11.008 (Epub ahead of print).","journal-title":"J Clin Lipidol."},{"key":"864_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.atherosclerosis.2013.09.020","volume":"231","author":"\u017d Reiner","year":"2013","unstructured":"Reiner \u017d, De Bacquer D, Kotseva K, Prugger C, De Backer G, Wood D, et al. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis. 2013;231:300\u20137.","journal-title":"Atherosclerosis."},{"key":"864_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jacl.2012.05.002","volume":"6","author":"PP T\u00f3th","year":"2012","unstructured":"T\u00f3th PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003\u20132006. J Clin Lipidol. 2012;6:325\u201330.","journal-title":"J Clin Lipidol."},{"key":"864_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12872-017-0591-5","volume":"17","author":"JP Halcox","year":"2017","unstructured":"Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord. 2017;17:160.","journal-title":"BMC Cardiovasc Disord."},{"key":"864_CR32","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/j.crvasa.2014.02.002","volume":"56","author":"B Nussbaumerov\u00e1","year":"2014","unstructured":"Nussbaumerov\u00e1 B, Rosolov\u00e1 H, Mayer O, Filipovsk\u00fd J, C\u00edfkov\u00e1 R, Bruthans J. Residual cardiovascular risk in patients with stable coronary heart disease over the last 16 years (Czech part of the EUROASPIRE I\u2013IV surveys). Cor et Vasa. 2014;56:e98\u2013104.","journal-title":"Cor et Vasa."},{"key":"864_CR33","first-page":"811","volume":"31","author":"JD Brunzell","year":"2008","unstructured":"Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;31:811\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"864_CR34","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"The Emerging Risk Factors Collaboration","year":"2009","unstructured":"The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993\u20132000.","journal-title":"JAMA"},{"key":"864_CR35","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572\u201380.","journal-title":"Lancet"},{"key":"864_CR36","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109\u201322.","journal-title":"N Engl J Med"},{"key":"864_CR37","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"AIM-HIGH Investigators","year":"2011","unstructured":"AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367.","journal-title":"N Engl J Med"},{"key":"864_CR38","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089\u201399.","journal-title":"N Engl J Med"},{"key":"864_CR39","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","volume":"34","author":"HPS2-THRIVE Collaborative Group","year":"2013","unstructured":"HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279\u201391.","journal-title":"Eur Heart J"},{"key":"864_CR40","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933\u201342.","journal-title":"N Engl J Med"},{"key":"864_CR41","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","volume":"123","author":"M Miller","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292\u2013333.","journal-title":"Circulation"},{"key":"864_CR42","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/eurheartj\/ehu500","volume":"36","author":"P Libby","year":"2015","unstructured":"Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J. 2015;36:774\u20136.","journal-title":"Eur Heart J"},{"key":"864_CR43","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37:1944\u201358.","journal-title":"Eur Heart J"},{"key":"864_CR44","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1161\/01.CIR.101.24.2777","volume":"101","author":"MA Austin","year":"2000","unstructured":"Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty BM, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation. 2000;101:2777\u201382.","journal-title":"Circulation"},{"key":"864_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jama.298.3.299","volume":"298","author":"BG Nordestgaard","year":"2007","unstructured":"Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299\u2013308.","journal-title":"JAMA"},{"key":"864_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.298.3.309","volume":"298","author":"S Bansal","year":"2007","unstructured":"Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309\u201316.","journal-title":"JAMA"},{"key":"864_CR47","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","volume":"51","author":"M Miller","year":"2008","unstructured":"Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E, PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724\u201330.","journal-title":"J Am Coll Cardiol."},{"key":"864_CR48","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","volume":"104","author":"O Faergeman","year":"2009","unstructured":"Faergeman O, Holme I, Fayyad R, Bhatia S, Grundy SM, Kastelein JJ, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104:459\u201363.","journal-title":"Am J Cardiol"},{"key":"864_CR49","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","volume":"117","author":"JJ Kastelein","year":"2008","unstructured":"Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002\u20139.","journal-title":"Circulation"},{"key":"864_CR50","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","volume":"65","author":"GG Schwartz","year":"2015","unstructured":"Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65:2267\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"864_CR51","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/ATVBAHA.116.307601","volume":"36","author":"R Puri","year":"2016","unstructured":"Puri R, Nissen SE, Shao M, Elshazly MB, Kataoka Y, Kapadia SR, et al. Non-HDL cholesterol and triglycerides: implications for coronary atheroma progression and clinical events. Arterioscler Thromb Vasc Biol. 2016;36:2220\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"864_CR52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1161\/CIRCOUTCOMES.115.002104","volume":"9","author":"R Klempfner","year":"2016","unstructured":"Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry. Circ Cardiovasc Qual Outcomes. 2016;9:100\u20138.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"864_CR53","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Eng J Med. 2010;362:1563\u201374.","journal-title":"N Eng J Med."},{"key":"864_CR54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/dom.13537","volume":"21","author":"GA Nichols","year":"2019","unstructured":"Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab. 2019;21:366\u201371.","journal-title":"Diabetes Obes Metab"},{"key":"864_CR55","doi-asserted-by":"publisher","first-page":"e008740","DOI":"10.1161\/JAHA.118.008740","volume":"7","author":"PP Toth","year":"2018","unstructured":"Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7:e008740.","journal-title":"J Am Heart Assoc."},{"key":"864_CR56","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626\u201335.","journal-title":"Lancet"},{"key":"864_CR57","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","volume":"49","author":"M Adiels","year":"2006","unstructured":"Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755\u201365.","journal-title":"Diabetologia"},{"key":"864_CR58","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1073\/pnas.0538015100","volume":"100","author":"O Ziouzenkova","year":"2003","unstructured":"Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, Moller DE, et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA. 2003;100:2730\u20135.","journal-title":"Proc Natl Acad Sci USA."},{"key":"864_CR59","doi-asserted-by":"publisher","first-page":"25050","DOI":"10.1074\/jbc.M401028200","volume":"279","author":"A Augustus","year":"2004","unstructured":"Augustus A, Yagyu H, Haemmerle G, Bensadoun A, Vikramadithyan RK, Park SY, et al. Cardiac-specific knock-out of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression. J Biol Chem. 2004;279:25050\u20137.","journal-title":"J Biol Chem"},{"key":"864_CR60","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","volume":"115","author":"JD Brown","year":"2007","unstructured":"Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115:518\u201333.","journal-title":"Circulation"},{"key":"864_CR61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","volume":"52","author":"A Tikka","year":"2016","unstructured":"Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine. 2016;52:187\u201393.","journal-title":"Endocrine"},{"key":"864_CR62","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrendo.2017.119","volume":"13","author":"S Kersten","year":"2017","unstructured":"Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol. 2017;13:731\u20139.","journal-title":"Nat Rev Endocrinol."},{"key":"864_CR63","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1161\/ATVBAHA.115.305614","volume":"35","author":"J Bor\u00e9n","year":"2015","unstructured":"Bor\u00e9n J, Watts GF, Adiels M, S\u00f6derlund S, Chan DC, Hakkarainen A, et al. Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: multicenter tracer kinetic study. Arterioscler Thromb Vasc Biol. 2015;35:2218\u201324.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"864_CR64","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","volume":"15","author":"BG Nordestgaard","year":"1995","unstructured":"Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995;15:534\u201342.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"864_CR65","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1161\/01.ATV.8.4.421","volume":"8","author":"BG Nordestgaard","year":"1988","unstructured":"Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall. Arteriosclerosis. 1988;8:421\u20138.","journal-title":"Arteriosclerosis."},{"key":"864_CR66","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","volume":"138","author":"AJ Vallejo-Vaz","year":"2018","unstructured":"Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT Trial. Circulation. 2018;138:770\u201381.","journal-title":"Circulation"},{"key":"864_CR67","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.pharmthera.2013.11.008","volume":"141","author":"A Varbo","year":"2014","unstructured":"Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014;141:358\u201367.","journal-title":"Pharmacol Ther"},{"key":"864_CR68","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"864_CR69","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1373\/clinchem.2014.234146","volume":"61","author":"A Varbo","year":"2015","unstructured":"Varbo A, Freiberg JJ, Nordestgaard BG. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. Clin Chem. 2015;61:533\u201343.","journal-title":"Clin Chem"},{"key":"864_CR70","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","volume":"62","author":"AM Jepsen","year":"2016","unstructured":"Jepsen AM, Langsted A, Varbo A, Bang LE, Kamstrup PR, Nordestgaard BG. Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease. Clin Chem. 2016;62:593\u2013604.","journal-title":"Clin Chem"},{"key":"864_CR71","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1161\/01.CIR.80.3.719","volume":"80","author":"D Steinberg","year":"1989","unstructured":"Steinberg D, Carew TE, Fielding C, Fogelman AM, Mahley RW, Sniderman AD, et al. Lipoproteins and the pathogenesis of atherosclerosis. Circulation. 1989;80:719\u201323.","journal-title":"Circulation"},{"key":"864_CR72","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","volume":"60","author":"DB Zilversmit","year":"1979","unstructured":"Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473\u201385.","journal-title":"Circulation"},{"key":"864_CR73","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/ATVBAHA.116.308834","volume":"37","author":"SJ Bernelot Moens","year":"2017","unstructured":"Bernelot Moens SJ, Verweij SL, Schnitzler JG, Stiekema LCA, Bos M, Langsted A, et al. Remnant cholesterol elicits arterial wall inflammation and a multilevel cellular immune response in humans. Arterioscler Thromb Vasc Biol. 2017;37:969\u201375.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"864_CR74","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2018.294926","author":"SEJ Hansen","year":"2018","unstructured":"Hansen SEJ, Madsen CM, Varbo A, Nordestgaard BG. Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: a study of more than 115000 individuals from the general population. Clin Chem. 2018. https:\/\/doi.org\/10.1373\/clinchem.2018.294926 (Epub ahead of print).","journal-title":"Clin Chem."},{"key":"864_CR75","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/01.ATV.0000054194.78240.45","volume":"23","author":"LA Pennacchio","year":"2003","unstructured":"Pennacchio LA, Rubin EM. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol. 2003;23:529\u201334.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"864_CR76","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2011.07.019","volume":"219","author":"SK Nilsson","year":"2011","unstructured":"Nilsson SK, Heeren J, Olivecrona G, Merkel M. Apolipoprotein A\u2013V; a potent triglyceride reducer. Atherosclerosis. 2011;219:15\u201321.","journal-title":"Atherosclerosis."},{"key":"864_CR77","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jama.2017.0972","volume":"317","author":"AV Khera","year":"2017","unstructured":"Khera AV, Won HH, Peloso GM, O\u2019Dushlaine C, Liu D, Stitziel NO, Natarajan P, et al. Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease. JAMA. 2017;317:937\u201346.","journal-title":"JAMA"},{"key":"864_CR78","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1161\/01.CIR.96.6.1737","volume":"96","author":"BG Nordestgaard","year":"1997","unstructured":"Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation. 1997;96:1737\u201344.","journal-title":"Circulation"},{"key":"864_CR79","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32\u201341.","journal-title":"N Engl J Med"},{"key":"864_CR80","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22\u201331.","journal-title":"N Engl J Med."},{"key":"864_CR81","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","volume":"374","author":"FE Dewey","year":"2016","unstructured":"Dewey FE, Gusarova V, O\u2019Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374:1123\u201333.","journal-title":"N Engl J Med"},{"key":"864_CR82","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","volume":"374","author":"NO Stitziel","year":"2016","unstructured":"Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators, Stitziel NO, Stirrups KE, Masca NG, Erdmann J, Ferrario PG, K\u00f6nig IR, et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016;374:1134\u201344.","journal-title":"N Engl J Med."},{"key":"864_CR83","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69:2054\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"864_CR84","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1161\/01.CIR.102.16.1886","volume":"102","author":"FM Sacks","year":"2000","unstructured":"Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886\u201392.","journal-title":"Circulation"},{"key":"864_CR85","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/eurheartj\/ehs271","volume":"34","author":"C Zheng","year":"2013","unstructured":"Zheng C, Azcutia V, Aikawa E, Figueiredo JL, Croce K, Sonoki H, et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J. 2013;34:615\u201324.","journal-title":"Eur Heart J"},{"key":"864_CR86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/MOL.0000000000000372","volume":"28","author":"L Juntti-Berggren","year":"2017","unstructured":"Juntti-Berggren L, Berggren PO. Apolipoprotein CIII is a new player in diabetes. Curr Opin Lipidol. 2017;28:27\u201331.","journal-title":"Curr Opin Lipidol"},{"key":"864_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003","author":"SM Grundy","year":"2018","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.003 (Epub ahead of print).","journal-title":"J Am Coll Cardiol."},{"issue":"Suppl 1","key":"864_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP15672.GLSUPPL","volume":"21","author":"Y Handelsman","year":"2015","unstructured":"Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American association of clinical endocrinologists and american college of endocrinology\u2014clinical practice guidelines for developing a diabetes mellitus comprehensive care plan\u20142015. Endocr Pract. 2015;21(Suppl 1):1\u201387.","journal-title":"Endocr Pract."},{"key":"864_CR89","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2999\u20133058.","journal-title":"Eur Heart J"},{"key":"864_CR90","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMc1006407","volume":"363","author":"FM Sacks","year":"2010","unstructured":"Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363:692\u20134.","journal-title":"N Engl J Med"},{"key":"864_CR91","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","volume":"2","author":"MB Elam","year":"2017","unstructured":"Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2:370\u201380.","journal-title":"JAMA Cardiol."},{"key":"864_CR92","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090\u20138.","journal-title":"Lancet"},{"key":"864_CR93","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","volume":"3","author":"T Aung","year":"2018","unstructured":"Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials Involving 77 917 individuals. JAMA Cardiol. 2018;3:225\u201334.","journal-title":"JAMA Cardiol."},{"key":"864_CR94","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2018","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018;380:11\u201322.","journal-title":"N Engl J Med"},{"key":"864_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.03.008","volume":"205","author":"JC Fruchart","year":"2009","unstructured":"Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205:1\u20138.","journal-title":"Atherosclerosis."},{"key":"864_CR96","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1194\/jlr.M088419","volume":"59","author":"CN Brocker","year":"2018","unstructured":"Brocker CN, Patel DP, Velenosi TJ, Kim D, Yan T, Yue J, et al. Extrahepatic PPAR\u03b1 modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice. J Lipid Res. 2018;59:2140\u201352.","journal-title":"J Lipid Res"},{"key":"864_CR97","first-page":"1173","volume":"2","author":"H Gronemeyer","year":"1995","unstructured":"Gronemeyer H, Laudet V. Transcription factors 3: nuclear receptors. Protein Profile. 1995;2:1173\u2013308.","journal-title":"Protein Profile."},{"key":"864_CR98","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/j.1460-2075.1992.tb05072.x","volume":"11","author":"JD Tugwood","year":"1992","unstructured":"Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 50-flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 1992;11:433\u20139.","journal-title":"EMBO J"},{"key":"864_CR99","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1161\/01.RES.0000127122.22685.0A","volume":"94","author":"N Marx","year":"2004","unstructured":"Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168\u201378.","journal-title":"Circ Res"},{"key":"864_CR100","doi-asserted-by":"publisher","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","volume":"274","author":"P Delerive","year":"1999","unstructured":"Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274:32048\u201354.","journal-title":"J Biol Chem"},{"key":"864_CR101","first-page":"1013","volume":"16","author":"I Pineda Torra","year":"2002","unstructured":"Pineda Torra I, Jamshidi Y, Flavell DM, Fruchart JC, Staels B. Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol. 2002;16:1013\u201328.","journal-title":"Mol Endocrinol"},{"key":"864_CR102","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","volume":"39","author":"N Bougarne","year":"2018","unstructured":"Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, et al. Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation. Endocr Rev. 2018;39:760\u2013802.","journal-title":"Endocr Rev"},{"key":"864_CR103","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1161\/01.CIR.99.24.3125","volume":"99","author":"N Marx","year":"1999","unstructured":"Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125\u201331.","journal-title":"Circulation"},{"key":"864_CR104","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/384039a0","volume":"384","author":"PR Devchand","year":"1996","unstructured":"Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 1996;384:39\u201343.","journal-title":"Nature"},{"key":"864_CR105","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/01.CIR.103.2.207","volume":"103","author":"BP Neve","year":"2001","unstructured":"Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001;103:207\u201312.","journal-title":"Circulation"},{"key":"864_CR106","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1161\/01.CIR.103.2.213","volume":"103","author":"N Marx","year":"2001","unstructured":"Marx N, Mackman N, Schoenbeck U, Yilmaz N, Hombach V, Libby P, et al. PPAR\u03b1 activators inhibit tissue factor expression and activity in human monocytes. Circulation. 2001;103:213\u20139.","journal-title":"Circulation"},{"key":"864_CR107","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.tem.2012.05.001","volume":"23","author":"W Wahli","year":"2012","unstructured":"Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012;23:351\u201363.","journal-title":"Trends Endocrinol Metab"},{"key":"864_CR108","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/ncpcardio1278","volume":"5","author":"B Staels","year":"2008","unstructured":"Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2008;5:542\u201353.","journal-title":"Nat Clin Pract Cardiovasc Med."},{"key":"864_CR109","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ceb.2015.02.003","volume":"33","author":"L Shi","year":"2015","unstructured":"Shi L, Tu BP. Acetyl-CoA and the regulation of metabolism: mechanisms and consequences. Curr Opin Cell Biol. 2015;33:125\u201331.","journal-title":"Curr Opin Cell Biol"},{"key":"864_CR110","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3389\/fimmu.2018.01605","volume":"9","author":"A Angajala","year":"2018","unstructured":"Angajala A, Lim S, Phillips JB, Kim JH, Yates C, You Z, et al. Diverse roles of mitochondria in immune responses: novel insights into immuno-metabolism. Front Immunol. 2018;9:1605.","journal-title":"Front Immunol"},{"key":"864_CR111","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0083-6729(00)60018-3","volume":"60","author":"V Krishnan","year":"2000","unstructured":"Krishnan V, Heath H, Bryant HU. Mechanism of action of estrogens and selective estrogen receptor modulators. Vitam Horm. 2000;60:123\u201347.","journal-title":"Vitam Horm"},{"key":"864_CR112","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.mrfmmm.2005.02.028","volume":"591","author":"JS Lewis","year":"2005","unstructured":"Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res. 2005;591:247\u201363.","journal-title":"Mutat Res"},{"key":"864_CR113","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1475-2840-12-82","volume":"12","author":"JC Fruchart","year":"2013","unstructured":"Fruchart JC. Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists. Cardiovasc Diabetol. 2013;12:82.","journal-title":"Cardiovasc Diabetol."},{"key":"864_CR114","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1001\/jama.297.12.1362","volume":"297","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Nicholls SJ, Wolski K, Howey DC, McErlean E, Wang MD, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007;297:1362\u201373.","journal-title":"JAMA"},{"key":"864_CR115","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.1016\/j.bmcl.2007.05.066","volume":"17","author":"Y Yamazaki","year":"2007","unstructured":"Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, et al. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. Bioorg Med Chem Lett. 2007;17:4689\u201393.","journal-title":"Bioorg Med Chem Lett"},{"key":"864_CR116","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bbrc.2018.03.135","volume":"499","author":"Y Yamamoto","year":"2018","unstructured":"Yamamoto Y, Takei K, Arulmozhiraja S, Sladek V, Matsuo N, Han SI, et al. Molecular association model of PPAR\u03b1 and its new specific and efficient ligand, pemafibrate: structural basis for SPPARM\u03b1. Biochem Biophys Res Commun. 2018;499:239\u201345.","journal-title":"Biochem Biophys Res Commun"},{"key":"864_CR117","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.diabet.2015.02.002","volume":"41","author":"A Besseiche","year":"2015","unstructured":"Besseiche A, Riveline JP, Gautier JF, Br\u00e9ant B, Blondeau B. Metabolic roles of PGC-1\u03b1 and its implications for type 2 diabetes. Diabetes Metab. 2015;41:347\u201357.","journal-title":"Diabetes Metab."},{"key":"864_CR118","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","volume":"16","author":"JC Fruchart","year":"2017","unstructured":"Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017;16:124.","journal-title":"Cardiovasc Diabetol."},{"key":"864_CR119","doi-asserted-by":"publisher","first-page":"754","DOI":"10.5551\/jat.28720","volume":"22","author":"S Raza-Iqbal","year":"2015","unstructured":"Raza-Iqbal S, Tanaka T, Anai M, Matsumura Y, Ikeda K, Taguchi A, et al. Transcriptome analysis of K-877 (a novel Selective PPAR\u03b1 Modulator (SPPARM\u03b1))-regulated genes in primary human hepatocytes and the mouse liver. J Atheroscler Thromb. 2015;22:754\u201372.","journal-title":"J Atheroscler Thromb."},{"key":"864_CR120","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.tem.2015.09.007","volume":"26","author":"A Kharitonenkov","year":"2015","unstructured":"Kharitonenkov A, DiMarchi R. FGF21 Revolutions: recent advances illuminating FGF21 biology and medicinal properties. Trends Endocrinol Metab. 2015;26:608\u201317.","journal-title":"Trends Endocrinol Metab"},{"key":"864_CR121","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cmet.2016.01.006","volume":"23","author":"C Schlein","year":"2016","unstructured":"Schlein C, Talukdar S, Heine M, Fischer AW, Krott LM, Nilsson SK, et al. FGF21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues. Cell Metab. 2016;23:441\u201353.","journal-title":"Cell Metab"},{"key":"864_CR122","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1373\/clinchem.2016.270876","volume":"63","author":"KL Ong","year":"2017","unstructured":"Ong KL, O\u2019Connell R, Januszewski AS, Jenkins AJ, Xu A, Sullivan DR, et al. Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: results from the FIELD Study. Clin Chem. 2017;63:1261\u201370.","journal-title":"Clin Chem"},{"key":"864_CR123","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/jdi.12621","volume":"8","author":"K Takei","year":"2017","unstructured":"Takei K, Han SI, Murayama Y, Satoh A, Oikawa F, Ohno H, et al. Selective peroxisome proliferator-activated receptor-\u03b1 modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-\u03b1 pathway and improves lipid metabolism in mice. J Diabetes Investig. 2017;8:446\u201352.","journal-title":"J Diabetes Investig."},{"key":"864_CR124","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5551\/jat.39693","volume":"25","author":"M Sairyo","year":"2018","unstructured":"Sairyo M, Kobayashi T, Masuda D, Kanno K, Zhu Y, Okada T, et al. A novel selective PPAR Modulator (SPPARM), K-877 (pemafibrate), attenuates postprandial hypertriglyceridemia in mice. J Atheroscler Thromb. 2018;25:142\u201352.","journal-title":"J Atheroscler Thromb."},{"key":"864_CR125","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jphs.2017.02.003","volume":"133","author":"K Takei","year":"2017","unstructured":"Takei K, Nakagawa Y, Wang Y, Han SI, Satoh A, Sekiya M, et al. Effects of K-877, a novel selective PPAR\u03b1 modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice. J Pharmacol Sci. 2017;133:214\u201322.","journal-title":"J Pharmacol Sci."},{"key":"864_CR126","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","volume":"249","author":"N Hennuyer","year":"2016","unstructured":"Hennuyer N, Duplan I, Paquet C, Vanhoutte J, Woitrain E, Touche V, et al. The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis. 2016;249:200\u20138.","journal-title":"Atherosclerosis."},{"key":"864_CR127","first-page":"e86","volume":"115","author":"H Iwata","year":"2014","unstructured":"Iwata H, Murakami K, Ricchiuto P, Singh S, Libby P, Aikawa E. The novel PPAR\u03b1 selective agonist K-877 suppresses pro-inflammatory pathways and experimental arterial lesion formation. Circ Res. 2014;115:e86\u201393 (Abstract 24160).","journal-title":"Circ Res."},{"key":"864_CR128","doi-asserted-by":"publisher","first-page":"E2148","DOI":"10.3390\/ijms19072148","volume":"19","author":"M Araki","year":"2018","unstructured":"Araki M, Nakagawa Y, Oishi A, Han SI, Wang Y, Kumagai K, et al. The peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) agonist pemafibrate protects against diet-induced obesity in mice. Int J Mol Sci. 2018;19:E2148.","journal-title":"Int J Mol Sci."},{"key":"864_CR129","doi-asserted-by":"publisher","first-page":"42477","DOI":"10.1038\/srep42477","volume":"7","author":"Y Honda","year":"2017","unstructured":"Honda Y, Kessoku T, Ogawa Y, Tomeno W, Imajo K, Fujita K, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017;7:42477.","journal-title":"Sci Rep."},{"key":"864_CR130","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.metabol.2017.02.013","volume":"71","author":"T Maki","year":"2017","unstructured":"Maki T, Maeda Y, Sonoda N, Makimura H, Kimura S, Maeno S, et al. Renoprotective effect of a novel selective PPAR\u03b1 modulator K-877 in db\/db mice: a role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway. Metabolism. 2017;71:33\u201345.","journal-title":"Metabolism."},{"key":"864_CR131","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1373\/clinchem.2017.279463","volume":"64","author":"A Varbo","year":"2018","unstructured":"Varbo A, Freiberg JJ, Nordestgaard BG. Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the Copenhagen General Population Study. Clin Chem. 2018;64:219\u201330.","journal-title":"Clin Chem"},{"key":"864_CR132","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","volume":"249","author":"S Ishibashi","year":"2016","unstructured":"Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, et al. Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36\u201343.","journal-title":"Atherosclerosis."},{"key":"864_CR133","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5551\/jat.44412","volume":"25","author":"H Arai","year":"2018","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, K-877 Study Group. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25:521\u201338.","journal-title":"J Atheroscler Thromb."},{"key":"864_CR134","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S, K-877 Study Group. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12:173\u201384.","journal-title":"J Clin Lipidol."},{"key":"864_CR135","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","volume":"261","author":"H Arai","year":"2017","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, K-877 Study Group. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017;261:144\u201352.","journal-title":"Atherosclerosis."},{"key":"864_CR136","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2337\/dc17-1589","volume":"41","author":"E Araki","year":"2018","unstructured":"Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, et al. Effects of pemafibrate, a novel selective PPAR\u03b1 modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41:538\u201346.","journal-title":"Diabetes Care"},{"key":"864_CR137","first-page":"1048","volume":"36","author":"JJP Kastelein","year":"2015","unstructured":"Kastelein JJP, Senko Y, Hounslow N. K-877, a selective PPAR alpha modulator (SPPARM alpha), improves dyslipidaemia in statin-treated patients with type 2 diabetes mellitus. Eur Heart J. 2015;36:1048.","journal-title":"Eur Heart J."},{"key":"864_CR138","first-page":"1048","volume":"36","author":"JJP Kastelein","year":"2015","unstructured":"Kastelein JJP, Senko Y, Hounslow N, Hovingh GK, Ginsberg HN. K-877, a selective PPAR alpha modulator (SPPARM alpha), ameliorates dyslipidaemia in patients with well-controlled LDL Cholesterol levels on statin therapy, without increases in serum creatinine. Eur Heart J. 2015;36:1048.","journal-title":"Eur Heart J."},{"key":"864_CR139","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jacl.2018.06.010","volume":"12","author":"S Yamashita","year":"2018","unstructured":"Yamashita S, Arai H, Yokote K, Araki E, Suganami H, Ishibashi S, K-877 Study Group. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. J Clin Lipidol. 2018;12:1267\u201379.","journal-title":"J Clin Lipidol."},{"key":"864_CR140","first-page":"155","volume":"32","author":"N Hounslow","year":"2018","unstructured":"Hounslow N, Mair S, Suganami H, Nakamura M. Pemafibrate has high bioavailability and is principally excreted via the liver. Atheroscler Suppl. 2018;32:155.","journal-title":"Atheroscler Suppl"},{"key":"864_CR141","doi-asserted-by":"publisher","first-page":"E706","DOI":"10.3390\/ijms20030706","volume":"20","author":"K Yokote","year":"2019","unstructured":"Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S. Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator (SPPARM\u03b1), in dyslipidemic patients with renal impairment. Int J Mol Sci. 2019;20:E706.","journal-title":"Int J Mol Sci"},{"key":"864_CR142","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.atherosclerosissup.2018.04.471","volume":"32","author":"K Yokote","year":"2018","unstructured":"Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S. A pooled analysis of pemafibrate Phase II\/III clinical trials indicated significant improvement in glycemic and liver function-related parameters. Atheroscler Suppl. 2018;32:155.","journal-title":"Atheroscler Suppl"},{"key":"864_CR143","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12845","author":"I Matsuba","year":"2018","unstructured":"Matsuba I, Matsuba R, Ishibashi S, Yamashita S, Arai H, Yokote K, et al. Effects of a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. J Diabetes Investig. 2018. https:\/\/doi.org\/10.1111\/jdi.12845 .","journal-title":"J Diabetes Investig."},{"key":"864_CR144","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","volume":"206","author":"AD Pradhan","year":"2018","unstructured":"Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018;206:80\u201393.","journal-title":"Am Heart J"},{"key":"864_CR145","unstructured":"PROMINENT-Eye Ancillary Study (Protocol AD). ClinicalTrials.gov Identifier NCT03345901. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03345901 . Accessed 7 Aug 2018."},{"key":"864_CR146","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","volume":"370","author":"AC Keech","year":"2007","unstructured":"Keech AC, Mitchell P, Summanen PA, O\u2019Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687\u201397.","journal-title":"Lancet"},{"key":"864_CR147","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1001288","volume":"363","author":"EY Chew","year":"2010","unstructured":"ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233\u201344.","journal-title":"N Engl J Med."},{"key":"864_CR148","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/MCG.0000000000000925","volume":"52","author":"I Doycheva","year":"2018","unstructured":"Doycheva I, Issa D, Watt KD, Lopez R, Rifai G, Alkhouri N. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in young adults in the United States. J Clin Gastroenterol. 2018;52:339\u201346.","journal-title":"J Clin Gastroenterol"},{"key":"864_CR149","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138\u201353.","journal-title":"Gut"},{"key":"864_CR150","unstructured":"A study of pemafibrate in patients with nonalcoholic fatty liver disease (NAFLD). ClinicalTrials.gov Identifier. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03350165 . Accessed 21 Jan 2019."},{"key":"864_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/db18-1153-p","volume":"67","author":"Y Sasaki","year":"2018","unstructured":"Sasaki Y, Asahiyama M, Kamiya W, Sakai J, Kodama T, Tanaka T. Tofogliflozin and pemafibrate combination therapy prevents nonalcoholic steatohepatitis (NASH) development of novel metabolic syndrome-related NASH model mice. Diabetes. 2018;67:1. https:\/\/doi.org\/10.2337\/db18-1153-p .","journal-title":"Diabetes."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0864-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-019-0864-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0864-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T11:19:17Z","timestamp":1663586357000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0864-7"}},"subtitle":["A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation"],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":151,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0864-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]},"assertion":[{"value":"24 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The following authors report disclosures outside the submitted work. These relate to grants and personal fees (honoraria for consultancy, lectures and\/or advisory bureaux). J-C Fruchart reports personal fees from Kowa Company. RD Santos reports personal fees from Amgen, AstraZeneca, Merck, Akcea, Sanofi\/Regeneron, Biolab, Esperion, Kowa, and Novo-Nordisk. M Aikawa reports grants from Kowa Company, Ltd., Pfizer, Inc., and Sanofi, Inc. P Amarenco reports personal fees from Kowa, grants and personal fees from Pfizer, Sanofi, Bristol Myers Squibb, Boston Scientific and AstraZeneca, grants from Merck, and personal fees from Amgen, GSK, Fibrogen and Shin Poong. PJ Barter reports personal fees from Amgen, Sanofi, and Pfizer. A Corsini reports personal fees from AstraZeneca, Amgen, Sanofi, Recordati, Novartis, MSD, Mediolanum, DOC, Mylan and Pfizer. RH Eckel reports grants from NINDS, NIA, NHLBI, Ionis Pharmaceutical, Uniqure Biopharma, CTSA Pilot Project, Endece, LLC, personal fees from Cardiometabolic Health Congress, Prime, Medtelligence, Medscape, Medical Education Resources, Vox Media, Sanofi\/Regeneron, Merck, Novo Nordisk, and Kowa. M Farnier reports grants, consulting fees and\/or honoraria for delivering lectures for Abbott, Akcea\/Ionis, Amarin, Amgen, AstraZeneca, Daiichi-Sankyo, Eli Lilly, Kowa, Merck and Co, Mylan, Pfizer, Sanofi\/Regeneron and Servier. HN Ginsberg reports and consults for Kowa, a pharmaceutical company that has a SPPARMalpha in clinical trials for the treatment of dyslipidemia and prevention of cardiovascular disease. MP Hermans reports personal fees from Amgen, AstraZeneca, MSD, Mylan, Sanofi-Aventis, Teva, and Tilman. S Ishibashi reports personal fees from Kowa, grants from Astellas Pharma, Boehringer Ingelheim, Daiichi Sankyo, Ono Pnharma, Shionogi, and Teijin Pharma. T Kodama is the recipient of a research grant from Kowa Company. W Koenig reports personal fees from AstraZeneca, Novartis, Pfizer, The Medicines Company, GSK, DalCor, Sanofi, Berlin-Chemie, Kowa, Amgen, grants and non-financial support from Roche Diagnostics, Beckmann, Singulex, and Abbott. M Krempf reports personal fees from Amgen, Sanofi Regeneron, MSD, Novartis, Abbott, Servier, AstraZeneca and grants from Pfizer. P Libby reports a research grant from Novartis and honoraria as a scientific advisory board member for Dalcor Pharmaceuticals. He also provides unpaid consultancy for Amgen, AstraZeneca, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Pfizer, Sanofi-Regeneron, XBiotech Inc., Corvidia Therapeutics, IFM Therapeutics, Olatec Therapeutics, Medimmune and Esperion Therapeutics. AJ Lorenzatti reports grants and personal fees from Amgen, Kowa, personal fees from Sanofi, Pfizer, and grants from Resverlogix. BG Nordestgaard reports personal fees from AstraZeneca, Sanofi, Regeneron, Ionis, Akcea, Amgen, Kowa, Denka Seiken, Amarin and Kowa. CJ Packard reports grants from MSD, and personal fees from Sanofi\/Regeneron, Amgen, and Daiichi-Sankyo. A Pradhan reports grants from Kowa Research Institute. KK Ray reports grants from Sanofi, Regeneron, Pfizer, Amgen, MSD, and honoraria for lectures\/speaker\u2019s bureau or consultancy from Sanofi, Amgen, Regeneron, Lilly, Medicines Company, Astra Zeneca, Pfizer, Kowa, Algorithm, IONIS, Esperion, Novo Nordisk, Takeda, Boehringer Ingelheim, Resverlogix, and Abbvie. Z Reiner reports personal fees from Sanofi Aventis and Akcea. PM Ridker reports grants from Kowa, Inc, Novartis, and Pfizer. H Shimano reports grants and personal fees from Kowa Company Ltd., Kowa Pharmaceutical Co. Ltd., MSD K.K., DAIICHI SANKYO Co., Ltd., Takeda Pharmaceutical Co.,Ltd., Astellas Pharma Inc., AstraZeneca K.K., ONO PHARMACEUTICAL CO., LTD., Nippon Boehringer lngelheim Co., Ltd., Eli Lilly Japan, Mitsubishi Tanabe Pharma Corporation, Sanofi K.K., MOCHIDA PHARMACEUTICAL CO., LTD., Novartis Pharma K.K., Bayer Yakuhin, Ltd., SHIONOGI & CO., LTD., and Taisho Toyama Pharmaceutical Co., Ltd. A Susekov reports personal fees from AstraZeneca, Pfizer, Sanofi, KRKA, Teva and Kowa. MR Taskinen reports grants and personal fees from Amgen, NovoNordisk, and personal fees from Sanofi and Akcea. LS Tokg\u00f6zo\u011flu reports personal fees from Abbott, Merck, Amgen, Astra, Novartis, Daiichi Sankyo, Pfizer, Actelion, Servier, Sanofi, Menarini, Mylan, Recordati and Novonordisk. B Tomlinson reports grants from Amgen, Merck Sharp and Dohme, Pfizer, Roche, and personal fees from Amgen, Dr. Reddy\u2019s Laboratories Ltd, Merck Serono and Sanofi. P Valensi reports personal fees from Abbott, AstraZeneca, Merck-Sharp Dohme, Novo-Nordisk, and Sanofi-Aventis. M Vrabl\u00edk reports personal fees from Abbott, Actavis, AstraZeneca, Amgen, BMS, Genzyme, KRKA, MSD Idea, Novartis, Pfizer and Sanofi-Regeneron. GF Watts reports support from Kowa for a lecture in Japan; honoraria (for advisory boards and lectures) and research grants from Amgen, Sanofi, and Regeneron; and honoraria (for advisory board) from Gemphire. S Yamashita reports grants and personal fees from Kowa Company, Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Bayer Yakuhin, Ltd., MSD K.K., Takeda Pharmaceutical Company, Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Astellas Pharma Inc., Daiichi-Sankyo Company, Ltd., Astra Zeneka K.K., Kaken Pharmaceutical Co., Ltd., grants from Nippon Boehringer Ingelheim Co., Ltd., National Institute of Biomedical Innovation, Kyowa Medex Co., Ltd., Mochida Pharmaceutical Company, Ltd., Hayashibara Co., Ltd., Teijin Pharma Limited and Kissei; and personal fees from Ono Pharmaceutical Company, Ltd., Skylight Biotec, Inc., Pfizer, Astellas Amgen, Sanofi, and Aegerion In addition, S Yamashita has a patent PCT\/JP2016\/074402 (Assisting Method for the Diagnosis of Type III Hyperlipidemia) pending to Fujirebio & Osaka University, a patent PCT\/JP2017\/038766 (Method for Selecting Subject Needing Treatment for Dyslipidemia and Reagent for Such Selection) pending to Osaka University & Kyowa Medex Co., Ltd., and a patent PCT\/JP2017\/038715 (Method for Measuring Oxidized High-Density Lipoprotein) pending to Osaka University & Kyowa Medex Co., Ltd.. A Zambon reports honoraria for lectures from Abbott, Amgen, Sanofi and Mylan. K Yokote reports grants and personal fees from Kowa Pharmaceutical Co, Astellas, AstraZeneca, MSD, Sanofi, Takeda, Pfizer, Mochida, and personal fees from Kowa Company, Astellas-Amgen Biopharm, and Bayer. C Aguilar-Salinas, K Al Rasadi, R Ceska, JP Despr\u00e9s, P Duriez, MV Ezhov, F Karpe, S Lim, R McPherson, J Millan Nu\u00f1ez-Cortes, H Ogawa, CI Ponte-Negretti, J Plutzky, M Ruscica, S Sadikot, P Sritara, JK Stock, T-C Su, A Tartar, A Tenenbaum, A Tybj\u00e6rg-Hansen, W Wahli have no competing interests in relation to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}